Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Ten Companies to Watch in AI Drug Discovery
Niven R. Narain emphasizes that AI investments in drug development require robust data and validation. GEN's A-List highlights 10 AI-based drug discovery leaders, including BPGbio, which focuses on cancer energy generation. Other notable companies include Nvidia and Palantir Technologies, though not on the A-List. The list includes specifics on companies like Anima Biotech, Atomwise, and Nimbus Therapeutics, detailing their AI platforms and drug development progress.
AI In Biotech Research: Boon Or Bane?
AI in biotechnology is transforming drug discovery, personalized medicine, and medical imaging. Despite challenges like talent shortages, regulatory issues, and cyber threats, AI's potential to revolutionize healthcare is significant. Companies like Exscientia, Insilico Medicine, and Recursion Pharmaceuticals are leading the charge. Legal considerations include data privacy, IP rights, and FDA compliance.
This week in AI research: Amazon launches 2T parameter video model, Mount Sinai opens ...
Amazon unveils 'Olympus' AI model with video analysis; Mount Sinai opens AI research center; Recursion Pharmaceuticals merges with Exscientia; IDEA Research's DINO-X improves object detection; Anthropic open-sources Model Context Protocol; AI talent shifts to major platforms; Bluesky faces data scraping incident; AstraZeneca partners with Lunit Oncology; South Korea launches AI Safety Institute; Commonwealth Bank of Australia enhances customer service with AI; majority of long-form content is AI-generated; Elon Musk's xAI scales infrastructure to compete with OpenAI.
Amendment: SEC Form SC 13G/A filed by Exscientia Plc
Novo Holdings A/S ceased to be a beneficial owner of more than 5% of Exscientia plc's Ordinary Shares due to Recursion Pharmaceuticals, Inc.'s purchase of Novo Holdings A/S's shares in the acquisition of Exscientia plc's entire issued share capital.
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine
Recursion and Exscientia complete AI-based drug development merger, creating a trans-Atlantic powerhouse with over 30 clinical and preclinical programs. The combined company, headquartered in Salt Lake City, focuses on oncology and rare diseases, with REC-617 (CDK7 inhibitor) and REC-994 (CCM treatment) as key candidates. The merger aims to generate $100 million in annual savings through operational synergies, including job cuts, and expects to receive over $20 billion in additional milestone payments from partnerships with Roche, Sanofi, Bayer, and others.
Recursion and Exscientia, two leaders in the AI drug
Recursion completes combination with Exscientia, creating a technology-enabled drug discovery platform with over 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs. The platform aims to reduce discovery time and cost, leveraging AI and proprietary data. Recursion will host an update call on November 20, 2024.
Recursion and Exscientia Combine to Advance the Industrialization of Drug Discovery
Recursion Pharmaceuticals completed its business combination with Exscientia, creating a leading AI-enabled drug discovery platform. The combined entity boasts over 10 clinical/preclinical programs, 10 advanced discovery programs, and 10+ partnered programs, aiming to reduce drug discovery time and cost. Updates on pipeline progress and partnerships were shared, with key data expected in 2024-2026.
Recursion and Exscientia Shareholders Approve the Proposed Combination
Recursion and Exscientia received shareholder approval for their proposed combination, expected to close on November 20, 2024. Recursion plans an update call after the close, to be broadcasted on X, LinkedIn, and YouTube. Chris Gibson, Recursion's CEO, expressed enthusiasm for combining Recursion's biological and chemical capabilities with Exscientia's molecular design and automated chemistry to accelerate drug discovery.
Inside the AI-Healthcare Boom: Breakthroughs in Diagnostics and Personalized Treatment
AI in healthcare is booming, with Mayo Clinic and Elon Musk's Grok AI leading the charge. Major tech companies like Nvidia, Google, and Microsoft showcased healthcare AI tools at the HLTH conference. Avant Technologies and Ainnova Tech formed a joint venture to advance early disease detection using AI, targeting a $67.4 billion market by 2027. Other companies like Recursion Pharmaceuticals, Exscientia, Absci Corporation, and Twist Bioscience are also making strides in AI-driven healthcare innovations.
Expanding Computer-Aided Drug Discovery With New AI Models
NVIDIA's BioNeMo AI toolkit, featuring models like DNABERT and scBERT, is revolutionizing drug discovery by enabling analysis of DNA sequences, protein interactions, and cell functions. Over 100 companies, including Cadence and Iambic Therapeutics, are integrating these AI tools to accelerate molecular simulations and drug design, reducing reliance on physical experiments.
© Copyright 2025. All Rights Reserved by MedPath